{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:32:53Z","timestamp":1775273573918,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004018","name":"Japanese Brain Bank Network for Neuroscience Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jchromb.2021.122885","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T16:29:20Z","timestamp":1630168160000},"page":"122885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["LC\u2013MS\/MS assay for the investigation of acetylated Alpha-synuclein in serum from postmortem Alzheimer\u2019s disease pathology"],"prefix":"10.1016","volume":"1181","author":[{"given":"Kazuki","family":"Uchida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Muguruma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaname","family":"Tsutsumiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daita","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Hashizume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Akatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2021.122885_b0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jchromb.2021.122885_b0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.pbr.2019.10.005","article-title":"Mechanisms of alpha-synuclein toxicity: an update and outlook","volume":"252","author":"Br\u00e1s","year":"2020","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.jchromb.2021.122885_b0015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bpa.12370","article-title":"Alpha-synuclein as a biomarker for Parkinson's disease","volume":"26","author":"Atik","year":"2016","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jchromb.2021.122885_b0020","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jnc.14809","article-title":"Parkinson's disease biomarkers based on \u03b1-synuclein","volume":"150","author":"Fayyad","year":"2019","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.jchromb.2021.122885_b0025","doi-asserted-by":"crossref","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical neurology and epidemiology of the major neurodegenerative diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jchromb.2021.122885_b0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.arr.2019.01.005","article-title":"Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: a meta-analysis of longitudinal studies","volume":"50","author":"Mueller","year":"2019","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.jchromb.2021.122885_b0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/brainsci11020215","article-title":"Cerebrospinal fluid biomarkers of Alzheimer's disease: current evidence and future perspectives","volume":"11","author":"McGrowder","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.jchromb.2021.122885_b0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0006-8993(00)03082-1","article-title":"Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation","volume":"888","author":"Arai","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.jchromb.2021.122885_b0045","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0002-9440(10)65722-7","article-title":"Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes","volume":"153","author":"Lippa","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jchromb.2021.122885_b0050","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jchromb.2021.122885_b0055","doi-asserted-by":"crossref","first-page":"10253","DOI":"10.1523\/JNEUROSCI.0581-12.2012","article-title":"Soluble \u03b1-synuclein is a novel modulator of Alzheimer's disease pathophysiology","volume":"32","author":"Larson","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jchromb.2021.122885_b0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt255","article-title":"Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease","volume":"6","author":"Hansson","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.jchromb.2021.122885_b0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.neulet.2011.09.063","article-title":"CSF \u03b1-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid \u03b2 in humans","volume":"504","author":"Spies","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jchromb.2021.122885_b0070","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jnnp.2009.197483","article-title":"Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease","volume":"81","author":"Kasuga","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jchromb.2021.122885_b0075","first-page":"1388","article-title":"Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson's disease","volume":"10","author":"Chang","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jchromb.2021.122885_b0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuroscience.2020.01.037","article-title":"Elevated serum \u03b1-synuclein levels in Huntington's disease patients","volume":"431","author":"Breza","year":"2020","journal-title":"Neuroscience"},{"key":"10.1016\/j.jchromb.2021.122885_b0085","first-page":"209","article-title":"Detection of \u03b1-synuclein in biological samples using mass spectrometry","volume":"2019","author":"Brinkmalm","year":"1948","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jchromb.2021.122885_b0090","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1021\/acs.jproteome.8b00982","article-title":"Mass spectrometric analysis of Lewy body-enriched \u03b1-synuclein in Parkinson's disease","volume":"18","author":"Bhattacharjee","year":"2019","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jchromb.2021.122885_b0095","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/ac403315h","article-title":"Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid-\u03b2 in Alzheimer's brain tissues by covalent chiral derivatized ultraperformance liquid chromatography tandem mass spectrometry","volume":"86","author":"Inoue","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2021.122885_b0100","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1039\/C9AN00751B","article-title":"Simultaneous quantification of tau and \u03b1-synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy body dementia from Alzheimer's disease and controls","volume":"144","author":"Viod\u00e9","year":"2019","journal-title":"Analyst"},{"key":"10.1016\/j.jchromb.2021.122885_b0105","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1373\/49.7.1041","article-title":"Ion suppression in mass spectrometry","volume":"49","author":"Annesley","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jchromb.2021.122885_b0110","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3233\/JAD-201038","article-title":"\u03b1-Synuclein heteromers in red blood cells of Alzheimer's disease and Lewy body dementia patients","volume":"80","author":"Daniele","year":"2021","journal-title":"J. Alzheimers Dis."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221003664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221003664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:06:31Z","timestamp":1761606391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023221003664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":22,"alternative-id":["S1570023221003664"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.122885","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC\u2013MS\/MS assay for the investigation of acetylated Alpha-synuclein in serum from postmortem Alzheimer\u2019s disease pathology","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.122885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122885"}}